Wakix Alternatives Compared
| Wakix | Xywav | Lumryz |
|
|---|
| Wakix (pitolisant) | Xywav (calcium oxybate / magnesium oxybate / potassium oxybate / sodium oxybate) | Lumryz (sodium oxybate) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Narcolepsy. Wakix may also be used for purposes not listed in this medication guide. |
Prescription only
Xywav may be used to treat idiopathic hypersomnia in adults or narcolepsy in adults and children aged 7 and older. It contains 92% less sodium than sodium oxybate (Xyrem) because it is made up of a... View more |
Prescription only
Prescribed for Idiopathic Hypersomnia, Cataplexy, Narcolepsy. Lumryz may also be used for purposes not listed in this medication guide. |
Related suggestions Popular comparisons
|
|||||||||||||||||||||||
| More about Wakix (pitolisant) | More about Xywav (calcium oxybate / magnesium oxybate / potassium oxybate / sodium oxybate) | More about Lumryz (sodium oxybate) | ||||||||||||||||||||||||
| Generic Status | ||||||||||||||||||||||||||
|
No lower-cost generic available |
No lower-cost generic available |
|||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Wakix has an average rating of 5.6 out of 10 from a total of 21 ratings on Drugs.com. 39% of reviewers reported a positive effect, while 33% reported a negative effect. |
Xywav has an average rating of 7.3 out of 10 from a total of 10 ratings on Drugs.com. 70% of reviewers reported a positive effect, while 20% reported a negative effect. |
Lumryz has an average rating of 10.0 out of 10 from a total of 1 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Side Effects | ||||||||||||||||||||||||||
|
See also: Wakix side effects in more detail. |
See also: Xywav side effects in more detail. |
See also: Lumryz side effects in more detail. |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Wakix prices |
View all Xywav prices |
View all Lumryz prices and generic prices |
||||||||||||||||||||||||
| Dosage Form(s) Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
N/A |
Other sodium oxybate brands include: Xyrem | ||||||||||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
|
24.2 hours |
0.66 hours |
1 hour |
||||||||||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Moderate abuse potential
Has a potential for abuse less than those in schedules 1 and 2. Has a currently accepted medical use in treatment in the United States. Abuse may lead to moderate or low physical dependence or high psychological dependence. |
Moderate abuse potential
Has a potential for abuse less than those in schedules 1 and 2. Has a currently accepted medical use in treatment in the United States. Abuse may lead to moderate or low physical dependence or high psychological dependence. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 461 drugs are known to interact with Wakix:
|
A total of 340 drugs are known to interact with Xywav:
|
A total of 340 drugs are known to interact with Lumryz:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
|
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
August 14, 2019 |
July 21, 2020 |
N/A |
||||||||||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.